Drug Interaction Report

Consumer information for this interaction is not currently available.

ADJUST DOSING INTERVAL: Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of rimegepant. In vitro, rimegepant is a substrate of the P-gp and breast cancer resistance protein (BCRP) efflux membrane transporters. In a dedicated drug interaction study, concomitant administration of rimegepant oral disintegrating tablet with cyclosporine, a potent P-gp and BCRP inhibitor, increased rimegepant peak plasma concentration (Cmax) and systemic exposure (AUC) by 1.4- and 1.6-fold, respectively. Coadministration with quinidine, a potent P-gp inhibitor, increased rimegepant Cmax and AUC by 1.7- and 1.6-fold, respectively. Based on the similar magnitude of interaction, BCRP inhibition alone is not expected to have a clinically significant impact on rimegepant exposures.

MANAGEMENT: The manufacturer recommends avoiding another dose of rimegepant within 48 hours when coadministered with a potent P-gp inhibitor.

If you are receiving therapy with rimegepant you may want to avoid the regular consumption of large amounts of grapefruits and grapefruit juice. Grapefruit can raise the levels of rimegepant in your body and lead to increased side effects. If grapefruit or grapefruit juice is consumed along with rimegepant, the manufacturer recommends avoiding a second dose of rimegepant within 48 hours. Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.